BioNTech
phase strong immunogenicity and promising clinical activity in cutaneous melanoma patients with evidence of disease and no evidence of disease nature | BioNTech
Company
Deck Type
Sector
Industry
Deck date
November 2021
Slide
22 of 40
Related slides by other companies
ATAI
Investor Presentation
January 2024
clinical evidence efficacy on cognitive in a phase study | ATAI
CG Oncology
IPO
March 2024
phase for high risk failure | CG Oncology
Genelux
Investor Presentation
December 2023
phase anti tumor activity as leading into combination a | Genelux
Genelux
Investor Presentation
February 2024
systemic administration demonstrated dose dependent benefit | Genelux
Other recent decks by BioNTech
See all presentations (12 decks)
Investor Presentation
August 2022
Results
August 2022
Investor Day
June 2022
Results
March 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io